Table 2 Logistic regression analysis of factors associated with the implementation of revascularization in patients with type 2 diabetes.

From: Factors associated with severe lower extremity artery disease in type 2 diabetes based on a large scale claims database in Japan

  

Odds ratio

95% CI

P value

Sex

Male

Reference

–

 
 

Female

0.50

0.41–0.60

< 0.001

Age/10years

 

1.30

1.16–1.47

< 0.001

BMI (kg/m2)

≥ 18.5

Reference

–

 
 

< 18.5

2.16

1.50–3.11

< 0.001

HbA1c (%)

≥ 7.0

Reference

–

 
 

< 7.0

0.63

0.53–0.75

< 0.001

eGFR (mL/min/1.73m2)

≥ 60

Reference

–

 
 

30 to <60

1.33

1.14–1.55

< 0.001

 

< 30

3.39

2.53–4.53

< 0.001

Diastolic blood pressure (mmHg)

≥ 80

Reference

–

 
 

< 80

1.54

1.32–1.80

< 0.001

Systolic blood pressure (mmHg)

≥ 130

Reference

–

 
 

< 130

0.83

0.69–0.99

0.048

HDL-C (mg/dL)

< 40

Reference

–

 
 

≥ 40

1.08

0.85–1.36

0.549

LDL-C (mg/dL)

≥ 120

Reference

–

 
 

< 120

0.95

0.83–1.10

0.526

TG (mg/dL)

≥ 150

Reference

–

 
 

< 150

0.88

0.76–1.01

0.077

Smoking history

No

Reference

–

 
 

Yes

2.05

1.75–2.40

< 0.001

Drinking history

Every day

Reference

–

 
 

Sometimes

1.05

0.85–1.29

0.667

 

Rarely

0.90

0.76–1.08

0.268

 

No

1.16

0.85–1.58

0.354

Anti-diabetic agent use

    

DPP-4is

 

0.94

0.79–1.11

0.445

Glinides

 

0.92

0.71–1.20

0.537

GLP-1 receptor agonists

 

–

–

 

Imeglimin

 

–

–

 

Insulin

 

1.41

1.19–1.67

< 0.001

Metformin

 

0.78

0.65–0.92

0.005

SGLT2is

 

0.50

0.41–0.60

< 0.001

Sulfonylureas

 

1.21

0.99–1.47

0.059

Thiazolidinediones

 

0.98

0.76–1.27

0.903

α-GIs

 

1.11

0.90–1.36

0.332

Antiplatelet drug use

    

Aspirin

 

1.99

1.67–2.36

< 0.001

P2Y12is

 

2.66

2.24–3.15

< 0.001

PDEis

 

7.15

6.11–8.38

< 0.001

Antihypertensive drug use

    

ACEis

 

0.83

0.67–1.04

0.103

Aldosterone receptor blocker

 

1.21

0.96–1.51

0.104

ARBs

 

1.41

1.19–1.66

< 0.001

ARNI

 

1.41

1.01–1.96

0.042

Calcium channel blockers

 

1.97

1.62–2.39

< 0.001

Loop diuretics

 

1.29

1.06–1.57

0.01

Thiazide diuretics

 

1.18

0.98–1.43

0.082

V2-Receptor blockers

 

1.03

0.72–1.49

0.855

α-Receptor blockers

 

1.43

1.15–1.78

0.001

β-Receptor blockers

 

1.89

1.62–2.20

< 0.001

Cholesterol-lowering drug use

    

Ezetimibe

 

0.85

0.68–1.07

0.166

Eicosapentaenoic acid

 

1.15

0.92–1.42

0.216

Fibrates

 

0.75

0.59–0.95

0.02

PCSK9is

–

–

–

 

Statins

 

0.88

0.75–1.03

0.117

  1. The data shows the results of the multivariate analysis. GLP-1 receptor agonist. Imeglimin, and PCSK9is were excluded from the univariate analysis.
  2. BMI body mass index, CI confidence interval, HbA1c hemoglobin A1c, eGFR estimated glomerular filtration rate, HDL-C high-density lipoprotein cholesterol, LDL-C low-density lipoprotein cholesterol, TG triglycerides, CKD chronic kidney disease, DPP-4is dipeptidyl peptidase-4 inhibitors, GLP-1 receptor agonists, glucagon-like peptide-1, SGLT2is sodium-glucose cotransporter 2 inhibitors, α-GI alpha-glucosidase inhibitor, PDEis phosphodiesterase inhibitors, ACEis angiotensin-converting enzyme inhibitors, ARBs angiotensin II receptor blockers, ARNI angiotensin receptor-neprilysin inhibitor, V2-Receptor blockers vasopressin V2 receptor blockers.
Back to article page